Abstract
Dual exemestane-everolimus therapy has been shown to confer a progression-free survival benefit in women with refractory advanced hormone-receptor-positive breast cancer. Patients with breast cancer may experience several other comorbidities, including hypertension, for which angiotensin-converting enzyme inhibitors (ACE-I) are a first-line therapy for hypertension of cardiovascular and/or renal etiology. One rare but feared side effect of ACE-I is severe angioedema due to decreased bradykinin degradation, which can lead to respiratory collapse. Several single-center case series have previously suggested that the use of everolimus in conjunction with ACE-I may lower the threshold for angioedema development. We report our experiences managing a 71-year-old with metastatic breast carcinoma and hypertension who presented with severe angioedema after the combined use of exemestane-everolimus with lisinopril.